What is Allurion?
Allurion operates at the forefront of the weight-loss industry, offering a comprehensive platform that integrates the Allurion Smart Capsule—the world's first swallowable, procedureless gastric balloon—with a sophisticated digital ecosystem. The company's Virtual Care Suite, which includes the Allurion Mobile App and the Iris AI Platform, provides healthcare providers with actionable insights to monitor and manage patient therapy. By digitizing the weight-loss journey, Allurion addresses the growing demand for non-invasive, technology-driven metabolic health interventions, positioning itself as a disruptive force in global healthcare markets.
How much funding has Allurion raised?
Allurion has raised a total of $281.3M across 16 funding rounds:
Private Equity
$6M
Multiple Rounds
$52M
Series B
$34M
Debt
$1M
Debt
$1M
Debt
$25M
Stock Offering
$100M
Debt
$48M
Share Placement
$2.3M
Stock/Share Issuance
$5M
Private Equity (2016): $6M backed by Romulus Capital
Private Equity (2017): $19M, investors not publicly disclosed
Series C (2017): $27M led by Romulus Capital and IDO Investments
Debt (2017): $6M supported by Silicon Valley Bank
Series B (2020): $34M featuring IDO Investments, Romulus Capital, Bridge Bank, and Novalis LifeSciences
Debt (2020): $1M backed by PPP
Debt (2021): $1M with participation from PPP
Debt (2021): $25M led by Runway Growth Capital LLC
Stock Issuance/Offering (2023): $100M, investors not publicly disclosed
Debt (2024): $48M featuring RTW Investments
Share Placement (2024): $2.3M, investors not publicly disclosed
Stock/Share Issuance (2025): $5M, investors not publicly disclosed
Key Investors in Allurion
Romulus Capital
Romulus Capital is an early-stage venture capital firm founded in 2008, focusing on leading Seed and Series A rounds for B2B companies that disrupt traditional industries or are deep technology firms emerging from elite research groups.
IDO Investments
IDO Investments is a technology investment firm based in Oman, focused on accelerating the growth of a knowledge-based economy by investing in established growth-stage startups that offer disruptive solutions.
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, providing both capital and scientific expertise to support transformative companies.
What's next for Allurion?
With the recent influx of capital, Allurion is well-positioned to scale its operational footprint and further refine its AI-driven clinical tools. The company's strategic roadmap likely involves expanding the availability of its Virtual Care Suite and advancing the clinical adoption of its investigational devices. As the firm transitions through its current lifecycle stage, the focus will remain on strengthening its market position, enhancing patient outcomes through data-driven personalization, and navigating the regulatory landscapes necessary for broader international deployment of its weight-loss technology.
See full Allurion company page
